Short Interest in Tiziana Life Sciences Ltd (NASDAQ:TLSA) Drops By 23.4%

Tiziana Life Sciences Ltd (NASDAQ:TLSA) was the target of a large drop in short interest in the month of February. As of February 15th, there was short interest totalling 934,300 shares, a drop of 23.4% from the January 31st total of 1,220,000 shares. Approximately 1.3% of the shares of the stock are short sold. Based on an average daily trading volume, of 690,700 shares, the days-to-cover ratio is currently 1.4 days.

Institutional Investors Weigh In On Tiziana Life Sciences

Several institutional investors and hedge funds have recently made changes to their positions in TLSA. Sanctuary Advisors LLC bought a new position in Tiziana Life Sciences during the 3rd quarter valued at about $864,000. Geode Capital Management LLC increased its holdings in shares of Tiziana Life Sciences by 12.4% during the fourth quarter. Geode Capital Management LLC now owns 245,722 shares of the company’s stock worth $171,000 after buying an additional 27,041 shares in the last quarter. Zhang Financial LLC increased its holdings in shares of Tiziana Life Sciences by 34.3% during the fourth quarter. Zhang Financial LLC now owns 93,187 shares of the company’s stock worth $65,000 after buying an additional 23,800 shares in the last quarter. Finally, Bison Wealth LLC bought a new position in shares of Tiziana Life Sciences in the fourth quarter valued at approximately $30,000.

Tiziana Life Sciences Stock Up 18.3 %

Shares of TLSA stock opened at $1.36 on Thursday. The stock’s fifty day simple moving average is $0.79 and its 200 day simple moving average is $0.90. Tiziana Life Sciences has a one year low of $0.41 and a one year high of $1.74.

Tiziana Life Sciences Company Profile

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases.